Wednesday, July 30, 2025 7/30/2025

Development of a radiation countermeasure with sex-dependent radiation response.

Award Number: R21AI193881
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/15/2025
PERIOD OF PERFORMANCE END DATE: 06/30/2027

Group Awards By:

View Award Description

Development of a radiation countermeasure with sex-dependent radiation response. - PROJECT SUMMARY/ABSTRACT The research goal is to understand the mechanism underlying sex-specific effects in the regulation of radiation response and to develop a novel radiation countermeasure that targets such differences. Radiation responses can vary between sexes. Women have a higher long-term risk of radiation-induced cancers than men. However, female mice reveal greater resistance to radiation and exhibit stronger short-term protective responses. Such differences in humans and rodents underscore the necessity for further research to uncover the underlying mechanisms and their implications for radiation biology and medicine. Radiation countermeasures are designed to reduce damages. Despite extensive research, only a few have received FDA approval. Challenges persist in addressing long-term radiation effects and understanding sex-related responses. Our published and preliminary studies showed female Lxn knockout (Lxn-/-) mice had increased hematopoietic stem/progenitor cell (HSPC) survival and regeneration in physiological condition by downregulating thrombospondin 1 (Thbs1). Lxn deletion enhances radiation-induced survival by mitigating hematopoietic-acute radiation response and delayed effects by upregulating Bcl-2. Surprisingly, the male Lxn-/- mice had no hematopoietic changes in physiological condition, which is mechanistically due to the sex-specific silence of Thbs1 gene expression. We screened a novel Lxn inhibitor that shows radiation mitigation effect in vitro and in vivo in female mice. We hypothesize that pharmaceutical and genetic inhibition of Lxn mitigates radiation injuries in a sex-dependent manner. Two aims will be proposed. Aim 1 is to determine the cellular and molecular mechanisms of Lxn deletion in radiation mitigation in male mice. Aim 2 is to determine whether Lxn inhibitor is a countermeasure with sex-specific radiation mitigation effect. The results will advance our understanding of the mechanisms underlying sex-specific regulation of radiation response and produce significant implications for accurate radiation risk assessments and targeted treatments in various radiation exposure scenarios.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $170,800 )
2025	2025	NEW YORK BLOOD CENTER, INC	310 E 67TH ST	NEW YORK	NY	10065	NEW YORK	USA	Allergy and Infectious Diseases Research	000	1	7/15/2025	NEW	$170,800
														Subtotal = $170,800

Grand Total All Awards = $170,800

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Development of a radiation countermeasure with sex-dependent radiation response.

Award Number: R21AI193881

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/15/2025

PERIOD OF PERFORMANCE END DATE: 06/30/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer